GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK plc (LSE/NYSE: LON:GSK) has announced positive outcomes from its phase III ANCHOR trials for depemokimab, a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). According to the press ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

Phase 3 trial results Depemokimab (GSK) Ultra-long acting biologic with high binding affinity for interleukin-5 For the treatment of severe asthma with type 2 inflammation. Phase 3 trial results ...

It can be used against a list of HRT products, including patches, tablets and topical preparations. According to the data, ...

Delhi HC closed contempt proceedings against Wikipedia after the platform globally removed a defamatory page. The court criticized Wikipedia for refusing to disclose user identities responsible ...